Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo

W. Huang, Zizheng Dong, Y. Chen, F. Wang, C. J. Wang, H. Peng, Y. He, G. Hangoc, Karen Pollok, George Sandusky, X. Y. Fu, Hal Broxmeyer, Zhong-Yin Zhang, J. Y. Liu, Jian-Ting Zhang

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Signal transducer and activator of transcription 3 (STAT3) is constitutively activated in malignant tumors and has important roles in multiple aspects of cancer aggressiveness. Thus targeting STAT3 promises to be an attractive strategy for treatment of advanced metastatic tumors. Although many STAT3 inhibitors targeting the SH2 domain have been reported, few have moved into clinical trials. Targeting the DNA-binding domain (DBD) of STAT3, however, has been avoided due to its ‘undruggable‘ nature and potentially limited selectivity. In a previous study, we reported an improved in silico approach targeting the DBD of STAT3 that resulted in a small-molecule STAT3 inhibitor (inS3-54). Further studies, however, showed that inS3-54 has off-target effect although it is selective to STAT3 over STAT1. In this study, we describe an extensive structure and activity-guided hit optimization and mechanistic characterization effort, which led to identification of an improved lead compound (inS3-54A18) with increased specificity and pharmacological properties. InS3-54A18 not only binds directly to the DBD and inhibits the DNA-binding activity of STAT3 both in vitro and in situ but also effectively inhibits the constitutive and interleukin-6-stimulated expression of STAT3 downstream target genes. InS3-54A18 is completely soluble in an oral formulation and effectively inhibits lung xenograft tumor growth and metastasis with little adverse effect on animals. Thus inS3-54A18 may serve as a potential candidate for further development as anticancer therapeutics targeting the DBD of human STAT3 and DBD of transcription factors may not be ‘undruggable‘ as previously thought.Oncogene advance online publication, 15 June 2015; doi:10.1038/onc.2015.215.

Original languageEnglish (US)
JournalOncogene
DOIs
StateAccepted/In press - Jun 15 2015

Fingerprint

STAT3 Transcription Factor
Neoplasm Metastasis
Gene Expression
DNA
Growth
Neoplasms
src Homology Domains
Oncogenes
Heterografts
Computer Simulation
Publications
Interleukin-6
Transcription Factors
Clinical Trials
Pharmacology

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo. / Huang, W.; Dong, Zizheng; Chen, Y.; Wang, F.; Wang, C. J.; Peng, H.; He, Y.; Hangoc, G.; Pollok, Karen; Sandusky, George; Fu, X. Y.; Broxmeyer, Hal; Zhang, Zhong-Yin; Liu, J. Y.; Zhang, Jian-Ting.

In: Oncogene, 15.06.2015.

Research output: Contribution to journalArticle

Huang, W. ; Dong, Zizheng ; Chen, Y. ; Wang, F. ; Wang, C. J. ; Peng, H. ; He, Y. ; Hangoc, G. ; Pollok, Karen ; Sandusky, George ; Fu, X. Y. ; Broxmeyer, Hal ; Zhang, Zhong-Yin ; Liu, J. Y. ; Zhang, Jian-Ting. / Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo. In: Oncogene. 2015.
@article{eee4ad16e1e34bcf97728e637c9d24ee,
title = "Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo",
abstract = "Signal transducer and activator of transcription 3 (STAT3) is constitutively activated in malignant tumors and has important roles in multiple aspects of cancer aggressiveness. Thus targeting STAT3 promises to be an attractive strategy for treatment of advanced metastatic tumors. Although many STAT3 inhibitors targeting the SH2 domain have been reported, few have moved into clinical trials. Targeting the DNA-binding domain (DBD) of STAT3, however, has been avoided due to its ‘undruggable‘ nature and potentially limited selectivity. In a previous study, we reported an improved in silico approach targeting the DBD of STAT3 that resulted in a small-molecule STAT3 inhibitor (inS3-54). Further studies, however, showed that inS3-54 has off-target effect although it is selective to STAT3 over STAT1. In this study, we describe an extensive structure and activity-guided hit optimization and mechanistic characterization effort, which led to identification of an improved lead compound (inS3-54A18) with increased specificity and pharmacological properties. InS3-54A18 not only binds directly to the DBD and inhibits the DNA-binding activity of STAT3 both in vitro and in situ but also effectively inhibits the constitutive and interleukin-6-stimulated expression of STAT3 downstream target genes. InS3-54A18 is completely soluble in an oral formulation and effectively inhibits lung xenograft tumor growth and metastasis with little adverse effect on animals. Thus inS3-54A18 may serve as a potential candidate for further development as anticancer therapeutics targeting the DBD of human STAT3 and DBD of transcription factors may not be ‘undruggable‘ as previously thought.Oncogene advance online publication, 15 June 2015; doi:10.1038/onc.2015.215.",
author = "W. Huang and Zizheng Dong and Y. Chen and F. Wang and Wang, {C. J.} and H. Peng and Y. He and G. Hangoc and Karen Pollok and George Sandusky and Fu, {X. Y.} and Hal Broxmeyer and Zhong-Yin Zhang and Liu, {J. Y.} and Jian-Ting Zhang",
year = "2015",
month = "6",
day = "15",
doi = "10.1038/onc.2015.215",
language = "English (US)",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo

AU - Huang, W.

AU - Dong, Zizheng

AU - Chen, Y.

AU - Wang, F.

AU - Wang, C. J.

AU - Peng, H.

AU - He, Y.

AU - Hangoc, G.

AU - Pollok, Karen

AU - Sandusky, George

AU - Fu, X. Y.

AU - Broxmeyer, Hal

AU - Zhang, Zhong-Yin

AU - Liu, J. Y.

AU - Zhang, Jian-Ting

PY - 2015/6/15

Y1 - 2015/6/15

N2 - Signal transducer and activator of transcription 3 (STAT3) is constitutively activated in malignant tumors and has important roles in multiple aspects of cancer aggressiveness. Thus targeting STAT3 promises to be an attractive strategy for treatment of advanced metastatic tumors. Although many STAT3 inhibitors targeting the SH2 domain have been reported, few have moved into clinical trials. Targeting the DNA-binding domain (DBD) of STAT3, however, has been avoided due to its ‘undruggable‘ nature and potentially limited selectivity. In a previous study, we reported an improved in silico approach targeting the DBD of STAT3 that resulted in a small-molecule STAT3 inhibitor (inS3-54). Further studies, however, showed that inS3-54 has off-target effect although it is selective to STAT3 over STAT1. In this study, we describe an extensive structure and activity-guided hit optimization and mechanistic characterization effort, which led to identification of an improved lead compound (inS3-54A18) with increased specificity and pharmacological properties. InS3-54A18 not only binds directly to the DBD and inhibits the DNA-binding activity of STAT3 both in vitro and in situ but also effectively inhibits the constitutive and interleukin-6-stimulated expression of STAT3 downstream target genes. InS3-54A18 is completely soluble in an oral formulation and effectively inhibits lung xenograft tumor growth and metastasis with little adverse effect on animals. Thus inS3-54A18 may serve as a potential candidate for further development as anticancer therapeutics targeting the DBD of human STAT3 and DBD of transcription factors may not be ‘undruggable‘ as previously thought.Oncogene advance online publication, 15 June 2015; doi:10.1038/onc.2015.215.

AB - Signal transducer and activator of transcription 3 (STAT3) is constitutively activated in malignant tumors and has important roles in multiple aspects of cancer aggressiveness. Thus targeting STAT3 promises to be an attractive strategy for treatment of advanced metastatic tumors. Although many STAT3 inhibitors targeting the SH2 domain have been reported, few have moved into clinical trials. Targeting the DNA-binding domain (DBD) of STAT3, however, has been avoided due to its ‘undruggable‘ nature and potentially limited selectivity. In a previous study, we reported an improved in silico approach targeting the DBD of STAT3 that resulted in a small-molecule STAT3 inhibitor (inS3-54). Further studies, however, showed that inS3-54 has off-target effect although it is selective to STAT3 over STAT1. In this study, we describe an extensive structure and activity-guided hit optimization and mechanistic characterization effort, which led to identification of an improved lead compound (inS3-54A18) with increased specificity and pharmacological properties. InS3-54A18 not only binds directly to the DBD and inhibits the DNA-binding activity of STAT3 both in vitro and in situ but also effectively inhibits the constitutive and interleukin-6-stimulated expression of STAT3 downstream target genes. InS3-54A18 is completely soluble in an oral formulation and effectively inhibits lung xenograft tumor growth and metastasis with little adverse effect on animals. Thus inS3-54A18 may serve as a potential candidate for further development as anticancer therapeutics targeting the DBD of human STAT3 and DBD of transcription factors may not be ‘undruggable‘ as previously thought.Oncogene advance online publication, 15 June 2015; doi:10.1038/onc.2015.215.

UR - http://www.scopus.com/inward/record.url?scp=84930995058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930995058&partnerID=8YFLogxK

U2 - 10.1038/onc.2015.215

DO - 10.1038/onc.2015.215

M3 - Article

C2 - 26073084

AN - SCOPUS:84958058999

JO - Oncogene

JF - Oncogene

SN - 0950-9232

ER -